Niraparib
Zejula (niraparib) is a prescription PARP inhibitor used for the maintenance treatment of ovarian, fallopian tube, and primary peritoneal cancer in patients who have responded to platinum-based chemotherapy. It is an oral medication that works by inhibiting PARP enzymes, which are involved in DNA repair in cancer cells.
Zejula is an oral PARP inhibitor used to maintain remission in ovarian cancer patients after chemotherapy.
Key facts at a glance
- RxNorm
- 1918237
- Generic
- Zejula
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Zejula is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It is also approved for the treatment of advanced ovarian cancer with homologous recombination deficiency (HRD) positivity.
Zejula works by inhibiting poly (ADP-ribose) polymerase (PARP) enzymes, which are involved in repairing DNA damage in cells. By blocking this repair mechanism, the medication causes DNA damage to accumulate in cancer cells, leading to cell death (apoptosis). This effect is particularly effective in cancer cells that already have defects in DNA repair pathways, such as those with BRCA mutations.
Zejula is a brand-name medication with no generic equivalent currently available. Common side effects may include fatigue, nausea, anemia, and low platelet counts. Regular blood monitoring is required during treatment. Patients should be advised to report any signs of bleeding, infection, or unusual bruising. Pregnancy should be avoided during treatment as the medication may harm an unborn baby. Always consult a healthcare provider for personalized medical advice before starting or stopping this medication.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy